膠肉腫の世界市場レポート 2025年

膠肉腫市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR5.3％で15億4,000万米ドルに成長します。予測期間における成長の原動力は、膠肉腫の罹患率の増加、脳腫瘍に対する意識の高まり、脳腫瘍に対する研究資金の増加、個別化治療に対する需要の高まり、ヘルスケアインフラの拡大であると予測されます。主な動向としては、診断技術の発展、標的療法の開発、高度な画像技術の利用可能性、手術技術の革新、ドラッグデリバリーシステムの技術的進歩などが挙げられます。

脳腫瘍の罹患率の上昇は、膠肉腫市場の成長を促進すると予想されます。脳腫瘍は脳内の細胞の異常増殖であり、良性または悪性の可能性があり、頭痛、発作、視力障害などの症状を引き起こすことがあります。脳腫瘍の症例数が増加しているのは、診断技術の向上、意識の高まり、危険因子にさらされやすい環境・生活習慣の要因によるものです。膠肉腫治療は、この攻撃的で稀ながんを管理する上で重要な役割を果たしており、症状の緩和、生存期間の延長、患者のQOLの向上を目指しています。例えば、2022年10月、米国連邦政府が運営する米国の生物医学図書館である国立医学図書館は、2023年に米国では脳および中枢神経系（CNS）腫瘍の新規症例が94,390例記録され、2022年の93,470例から増加したと報告しました。悪性症例は26,670例から26,940例に増加し、非悪性症例は66,800例から67,440例に増加しました。このように、脳腫瘍の罹患率の増加が膠肉腫治療への需要を促進しています。

膠肉腫市場の主要企業は、がん治療とモニタリングを強化するための高度なウェアラブル技術の開発に注力しています。ウェアラブルデバイスは、健康データを追跡・分析し、リアルタイムの洞察を提供し、患者エンゲージメントを向上させる、身体に装着する電子ガジェットです。例えば、2024年11月、英国を拠点とするオンコロジー企業であるNovocure Ltd.は、多形膠芽腫（GBM）の成人患者を治療するために、Optune GioとともにHead Flexible Electrode（HFE）トランスデューサアレイの使用について米国食品医薬品局（FDA）の承認を取得しました。Optune Gioは、非侵襲的なアレイを使用して腫瘍治療磁場（TTFields）を照射するポータブルでウェアラブルな装置であり、この磁場は分裂中のがん細胞の帯電成分に物理的な力を加え、その急速な増殖を阻害します。新たに導入されたHFEアレイは、既存のOptune Gioアレイで使用されているセラミックディスクよりも50％薄く、3分の1軽量であり、柔軟なポリマー素材で作られているため、患者の快適性と使いやすさが向上しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界膠肉腫PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の膠肉腫市場：成長率分析
• 世界の膠肉腫市場の実績：規模と成長, 2019-2024
• 世界の膠肉腫市場の予測：規模と成長, 2024-2029, 2034F
• 世界膠肉腫総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の膠肉腫市場診断方法別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 画像技術
• 組織病理学的検査
• バイオマーカー検査
• 世界の膠肉腫市場治療の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 手術
• 放射線治療
• 化学療法
• 標的療法
• 免疫療法
• 世界の膠肉腫市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• がん調査機関
• 専門クリニック
• 世界の膠肉腫市場、画像技術の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 磁気共鳴画像法（MRI）
• コンピュータ断層撮影（CT）スキャン
• 陽電子放出断層撮影（PET）スキャン
• 世界の膠肉腫市場、組織病理学的検査のサブセグメンテーション、種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ヘマトキシリン・エオシン（H&E）染色
• 免疫組織化学（IHC）
• 電子顕微鏡
• 世界の膠肉腫市場バイオマーカー検査の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• IDH変異検査
• MGMTプロモーターメチル化試験
• ATRX変異検査
• TP53変異解析

第7章 地域別・国別分析

• 世界の膠肉腫市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の膠肉腫市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 膠肉腫市場：競合情勢
• 膠肉腫市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Bristol-Myers Squibb Company
• Novartis AG
• Eli Lilly and Company
• Amgen Inc.
• Teva Pharmaceutical Industries Ltd.
• Regeneron Pharmaceuticals Inc.
• Sun Pharmaceutical Industries Ltd.
• Sumitomo Dainippon Pharma
• Bio-Rad Laboratories Inc.
• Carl Zeiss AG
• Elekta AB
• Novocure Ltd.
• ImmunityBio Inc.
• Immatics Biotechnologies
• Karyopharm Therapeutics Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 膠肉腫市場2029：新たな機会を提供する国
• 膠肉腫市場2029：新たな機会を提供するセグメント
• 膠肉腫市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Gliosarcoma is a rare and aggressive brain tumor composed of both glial and sarcomatous tissue, primarily occurring in the cerebral hemisphere. It is studied to understand tumor biology and develop treatment strategies for glioblastoma and other brain malignancies.

The primary diagnostic methods for gliosarcoma include imaging techniques, histopathological examination, and biomarker testing. Imaging techniques, such as MRI, CT, and PET scans, are non-invasive methods used to visualize internal structures and detect abnormalities. Treatment options include surgery, radiation therapy, chemotherapy, targeted therapy, and immunotherapy, with end users including hospitals, cancer research institutes, and specialty clinics.

The gliosarcoma market research report is one of a series of new reports from The Business Research Company that provides gliosarcoma market statistics, including gliosarcoma industry global market size, regional shares, competitors with a gliosarcoma market share, detailed gliosarcoma market segments, market trends and opportunities, and any further data you may need to thrive in the gliosarcoma industry. This gliosarcoma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The gliosarcoma market size has grown strongly in recent years. It will grow from $1.19 billion in 2024 to $1.25 billion in 2025 at a compound annual growth rate (CAGR) of 5.7%. The growth in the historic period was driven by increasing healthcare expenditure, a rising number of clinical trials, a growing global aging population, a higher prevalence of comorbidities such as diabetes and hypertension, and expanded healthcare insurance coverage.

The gliosarcoma market size is expected to see strong growth in the next few years. It will grow to $1.54 billion in 2029 at a compound annual growth rate (CAGR) of 5.3%. The growth in the forecast period is expected to be driven by the increasing incidence of gliosarcoma, rising awareness of brain cancers, growth in research funding for brain cancer, increasing demand for personalized treatments, and the expansion of healthcare infrastructure. Key trends include advancements in diagnostic techniques, the development of targeted therapies, the availability of advanced imaging technologies, innovations in surgical techniques, and technological advancements in drug delivery systems.

The rising incidence of brain tumors is expected to drive growth in the gliosarcoma market. A brain tumor is an abnormal growth of cells in the brain, which can be either benign or malignant and may cause symptoms such as headaches, seizures, and vision problems. The increasing number of brain tumor cases is attributed to improved diagnostic technologies, heightened awareness, and environmental and lifestyle factors that may contribute to greater exposure to risk factors. Gliosarcoma treatment plays a crucial role in managing this aggressive and rare cancer, aiming to alleviate symptoms, extend survival, and enhance the patient's quality of life. For example, in October 2022, the National Library of Medicine, a US-based biomedical library operated by the United States federal government, reported that in 2023, the United States recorded 94,390 new cases of brain and central nervous system (CNS) tumors, up from 93,470 cases in 2022. Malignant cases increased from 26,670 to 26,940, while non-malignant cases rose from 66,800 to 67,440. The growing incidence of brain tumors is thus fueling demand for gliosarcoma treatment.

Leading companies in the gliosarcoma market are focusing on developing advanced wearable technology to enhance cancer treatment and monitoring. Wearable devices are electronic gadgets worn on the body that track and analyze health data, offering real-time insights and improving patient engagement. For instance, in November 2024, Novocure Ltd., a UK-based oncology company, received U.S. Food and Drug Administration (FDA) approval for the use of Head Flexible Electrode (HFE) transducer arrays alongside Optune Gio for treating adult patients with glioblastoma multiforme (GBM). Optune Gio is a portable, wearable device that uses non-invasive arrays to deliver tumor-treating fields (TTFields), which apply physical forces to electrically charged components of dividing cancer cells, disrupting their rapid growth. The newly introduced HFE arrays are 50% thinner and one-third lighter than the ceramic discs used in the existing Optune Gio arrays, as they are made from a flexible polymer material, enhancing patient comfort and usability.

In October 2024, Merck & Co. Inc., a US-based pharmaceutical company, acquired Modifi Biosciences in a $1.3 billion deal. This acquisition strengthens Merck's oncology portfolio by advancing innovative therapies for glioblastoma and other cancers, further expanding its expertise in cancer treatment. Modifi Biosciences, based in the U.S., specializes in developing treatments for glioblastoma, reinforcing Merck's commitment to addressing complex oncological challenges.

Major players in the gliosarcoma market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Bristol-Myers Squibb Company, Novartis AG, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Sumitomo Dainippon Pharma, Bio-Rad Laboratories Inc., Carl Zeiss AG, Elekta AB, Novocure Ltd., ImmunityBio Inc., Immatics Biotechnologies, Karyopharm Therapeutics Inc., Celon Laboratories Pvt. Ltd., Komipharm International Co. Ltd., Kintara Therapeutics Inc., Aveta Biomics Inc., Vigeo Therapeutics Inc.

North America was the largest region in the gliosarcoma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in gliosarcoma report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the gliosarcoma market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The gliosarcoma market consists of revenues earned by entities by providing services such as molecular diagnostics, clinical trials and research, palliative care services, rehabilitation, and recovery support. The market value includes the value of related goods sold by the service provider or included within the service offering. The gliosarcoma market also includes sales of diagnostic kits, research reagents, and patient monitoring devices. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Gliosarcoma Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on gliosarcoma market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for gliosarcoma ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The gliosarcoma market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Diagnosis Method: Imaging Techniques; Histopathological Examination; Biomarker Testing
• 2) By Treatment Type: Surgery; Radiation Therapy; Chemotherapy; Targeted Therapy; Immunotherapy
• 3) By End-User: Hospitals; Cancer Research Institutes; Specialty Clinics
• Subsegments:
• 1) By Imaging Techniques: Magnetic Resonance Imaging (MRI); Computed Tomography (CT) Scan; Positron Emission Tomography (PET) Scan
• 2) By Histopathological Examination: Hematoxylin and Eosin (H&E) Staining; Immunohistochemistry (IHC); Electron Microscopy
• 3) By Biomarker Testing: IDH Mutation Testing; MGMT Promoter Methylation Testing; ATRX Mutation Testing; TP53 Mutation Analysis
• Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd.; Merck & Co. Inc.; AbbVie Inc.; Bayer AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Gliosarcoma Market Characteristics

3. Gliosarcoma Market Trends And Strategies

4. Gliosarcoma Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Gliosarcoma Growth Analysis And Strategic Analysis Framework

• 5.1. Global Gliosarcoma PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Gliosarcoma Market Growth Rate Analysis
• 5.4. Global Gliosarcoma Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Gliosarcoma Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Gliosarcoma Total Addressable Market (TAM)

6. Gliosarcoma Market Segmentation

• 6.1. Global Gliosarcoma Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Imaging Techniques
• Histopathological Examination
• Biomarker Testing
• 6.2. Global Gliosarcoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Surgery
• Radiation Therapy
• Chemotherapy
• Targeted Therapy
• Immunotherapy
• 6.3. Global Gliosarcoma Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Cancer Research Institutes
• Specialty Clinics
• 6.4. Global Gliosarcoma Market, Sub-Segmentation Of Imaging Techniques, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Magnetic Resonance Imaging (MRI)
• Computed Tomography (CT) Scan
• Positron Emission Tomography (PET) Scan
• 6.5. Global Gliosarcoma Market, Sub-Segmentation Of Histopathological Examination, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hematoxylin and Eosin (H&E) Staining
• Immunohistochemistry (IHC)
• Electron Microscopy
• 6.6. Global Gliosarcoma Market, Sub-Segmentation Of Biomarker Testing, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• IDH Mutation Testing
• MGMT Promoter Methylation Testing
• ATRX Mutation Testing
• TP53 Mutation Analysis

7. Gliosarcoma Market Regional And Country Analysis

• 7.1. Global Gliosarcoma Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Gliosarcoma Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Gliosarcoma Market

• 8.1. Asia-Pacific Gliosarcoma Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Gliosarcoma Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Gliosarcoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Gliosarcoma Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Gliosarcoma Market

• 9.1. China Gliosarcoma Market Overview
• 9.2. China Gliosarcoma Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Gliosarcoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Gliosarcoma Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Gliosarcoma Market

• 10.1. India Gliosarcoma Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Gliosarcoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Gliosarcoma Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Gliosarcoma Market

• 11.1. Japan Gliosarcoma Market Overview
• 11.2. Japan Gliosarcoma Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Gliosarcoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Gliosarcoma Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Gliosarcoma Market

• 12.1. Australia Gliosarcoma Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Gliosarcoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Gliosarcoma Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Gliosarcoma Market

• 13.1. Indonesia Gliosarcoma Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Gliosarcoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Gliosarcoma Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Gliosarcoma Market

• 14.1. South Korea Gliosarcoma Market Overview
• 14.2. South Korea Gliosarcoma Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Gliosarcoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Gliosarcoma Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Gliosarcoma Market

• 15.1. Western Europe Gliosarcoma Market Overview
• 15.2. Western Europe Gliosarcoma Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Gliosarcoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Gliosarcoma Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Gliosarcoma Market

• 16.1. UK Gliosarcoma Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Gliosarcoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Gliosarcoma Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Gliosarcoma Market

• 17.1. Germany Gliosarcoma Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Gliosarcoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Gliosarcoma Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Gliosarcoma Market

• 18.1. France Gliosarcoma Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Gliosarcoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Gliosarcoma Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Gliosarcoma Market

• 19.1. Italy Gliosarcoma Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Gliosarcoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Gliosarcoma Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Gliosarcoma Market

• 20.1. Spain Gliosarcoma Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Gliosarcoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Gliosarcoma Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Gliosarcoma Market

• 21.1. Eastern Europe Gliosarcoma Market Overview
• 21.2. Eastern Europe Gliosarcoma Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Gliosarcoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Gliosarcoma Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Gliosarcoma Market

• 22.1. Russia Gliosarcoma Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Gliosarcoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Gliosarcoma Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Gliosarcoma Market

• 23.1. North America Gliosarcoma Market Overview
• 23.2. North America Gliosarcoma Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Gliosarcoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Gliosarcoma Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Gliosarcoma Market

• 24.1. USA Gliosarcoma Market Overview
• 24.2. USA Gliosarcoma Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Gliosarcoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Gliosarcoma Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Gliosarcoma Market

• 25.1. Canada Gliosarcoma Market Overview
• 25.2. Canada Gliosarcoma Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Gliosarcoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Gliosarcoma Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Gliosarcoma Market

• 26.1. South America Gliosarcoma Market Overview
• 26.2. South America Gliosarcoma Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Gliosarcoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Gliosarcoma Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Gliosarcoma Market

• 27.1. Brazil Gliosarcoma Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Gliosarcoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Gliosarcoma Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Gliosarcoma Market

• 28.1. Middle East Gliosarcoma Market Overview
• 28.2. Middle East Gliosarcoma Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Gliosarcoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Gliosarcoma Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Gliosarcoma Market

• 29.1. Africa Gliosarcoma Market Overview
• 29.2. Africa Gliosarcoma Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Gliosarcoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Gliosarcoma Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Gliosarcoma Market Competitive Landscape And Company Profiles

• 30.1. Gliosarcoma Market Competitive Landscape
• 30.2. Gliosarcoma Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Bayer AG Overview, Products and Services, Strategy and Financial Analysis

31. Gliosarcoma Market Other Major And Innovative Companies

• 31.1. Bristol-Myers Squibb Company
• 31.2. Novartis AG
• 31.3. Eli Lilly and Company
• 31.4. Amgen Inc.
• 31.5. Teva Pharmaceutical Industries Ltd.
• 31.6. Regeneron Pharmaceuticals Inc.
• 31.7. Sun Pharmaceutical Industries Ltd.
• 31.8. Sumitomo Dainippon Pharma
• 31.9. Bio-Rad Laboratories Inc.
• 31.10. Carl Zeiss AG
• 31.11. Elekta AB
• 31.12. Novocure Ltd.
• 31.13. ImmunityBio Inc.
• 31.14. Immatics Biotechnologies
• 31.15. Karyopharm Therapeutics Inc.

32. Global Gliosarcoma Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Gliosarcoma Market

34. Recent Developments In The Gliosarcoma Market

35. Gliosarcoma Market High Potential Countries, Segments and Strategies

• 35.1 Gliosarcoma Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Gliosarcoma Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Gliosarcoma Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer